600165新日恒力是什么概念股

New Hengli (600165) is a concept stock that specializes in the production and sales of active carbon products, stem cell preparation and storage, and trade.

1. Advanced Product Technology and Strong Product Competitiveness

New Hengli's main business includes the production and sales of lauric acid, as well as other businesses such as the production and sales of active carbon products, stem cell preparation and storage, and trade. The company has introduced third-generation biotechnology from the Chinese Academy of Sciences to scale up the production of long-chain dicarboxylic acids. This advanced technology gives New Hengli a competitive edge in the market.

2. Pledge Ratio and Key Financial Data

As of December 8, 2023, New Hengli has a total pledge ratio of 29.2% and a total pledge of 200 million shares. The company's core financial data shows that it has no income, no price-earnings ratio, no net asset per share, and no price-to-book ratio. The total revenue is also not available.

3. Potential in the Bio-based Materials Industry

In the context of global energy transition, bio-based materials have great potential for development as they can effectively reduce carbon emissions. New Hengli's acquisition of the technology for producing long-chain dicarboxylic acids provides the company with a huge opportunity in the field of bio-based materials.

4. Major Asset Restructuring and Employee Stock Ownership

Since the approval of the 2015 Employee Stock Ownership Plan, New Hengli has undergone two major asset restructurings and non-public issuances in 2015 and 2016. These actions have played a significant role in the company's development.

5. Comparison with Kai Sai Biological

New Hengli's subsidiary, Hengli New Materials, has more advanced technology compared to Kai Sai Biological. The exclusive cooperation with the Chinese Academy of Sciences Microbiology Institute on the patent technology for lauric acid makes it a more advanced version of the third-generation biotechnology. Furthermore, China has already established a foothold in this field.

6. Technical Acceptance of the 50,000-ton/year Lauric Acid Project

New Hengli's 50,000-ton/year lauric acid project has passed technical acceptance and has reached the intended use state, demonstrating the company's successful implementation of this project.

In conclusion, New Hengli (600165) is a concept stock with advanced product technology and strong product competitiveness. With its focus on active carbon products, stem cell preparation and storage, and trade, the company has acquired cutting-edge biotechnology for the production of long-chain dicarboxylic acids. Furthermore, New Hengli's major asset restructuring and employee stock ownership plans have contributed significantly to its growth. The company has a promising future in the bio-based materials industry and has successfully completed the technical acceptance of its lauric acid project.